Blade Air Mobility Inc Q2 2025 Earnings: Revenue Surges to $70.8 Million, EPS Beats Estimates at $(0.03)

Blade Air Mobility Inc reported Q2 2025 revenue of $70.8 million, beating estimates of $64.08 million. The net loss was $3.7 million, a significant improvement from the $11.3 million loss in the same period last year. The company's Medical segment saw a 17.6% YoY increase in revenue, reaching $45.1 million. Blade announced the sale of its Passenger division to Joby Aviation for up to $125 million, focusing on its Medical division, which will be rebranded as Strata Critical Medical.

Blade Air Mobility Inc (NASDAQ: BLDE) reported its Q2 2025 financial results, with total revenue reaching $70.8 million, exceeding estimates of $64.08 million. The company's net loss narrowed significantly to $3.7 million from $11.3 million in the same period last year. The Medical segment saw a notable 17.6% year-over-year (YoY) increase in revenue, reaching $45.1 million, now representing over 60% of total revenue compared to just 12% in 2020. The company also announced the sale of its Passenger division to Joby Aviation for up to $125 million, with the Medical division rebranding as Strata Critical Medical.

The most transformative development was the announced sale of Blade's Passenger division to Joby Aviation for up to $125 million. This strategic divestiture will transform the company into a pure-play healthcare logistics business, rebranding as Strata Critical Medical. Management expects this transaction to be Adjusted EBITDA and Free Cash Flow neutral going forward, supported by approximately $7 million in corporate cost efficiencies. Flight margins improved to 25.1% from 24.1% in the prior year, with Passenger Flight Margin expanding significantly to 30.5% from 24.7%, demonstrating operational improvements despite revenue challenges in the Passenger segment. Medical segment Flight Margin decreased slightly to 22.0% from 23.6% due to maintenance issues. Post-transaction, Strata will maintain a strong financial position with approximately $200 million in cash and short-term investments.

The company reaffirmed its full-year guidance of $245-265 million in revenue and double-digit Adjusted EBITDA, though this will be updated after the transaction closes. This strategic pivot positions the company to focus exclusively on its faster-growing, more predictable medical transportation business with limited economic sensitivity and contractual revenue. The long-term partnership with Joby will provide access to eVTOL aircraft for medical transport, potentially creating competitive advantages through lower noise profiles and operating costs compared to traditional aircraft.

Reference List:
[1] https://www.stocktitan.net/news/BLDE/blade-air-mobility-announces-second-quarter-2025-rw8gh7uta691.html